MYC can induce global protein synthesis by stimulating ribosome biogenesis through the upregulation of multiple components including NPM1 and RNPs. 52, 57, 58 Here, we provided evidence that MYC ...

DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insight 2025” report provides comprehensive insights about 70+ ...

PIM protein kinases have been known for some time as oncogenes that promote lymphomagenesis together with MYC (c-Myc). It is now reported that PIM1 is a coactivator of MYC, and it phosphorylates ...

The presence of MYC translocation and high MYC mRNA expression have recently been associated with poor OS in patients with DLBCL treated with R-CHOP, raising questions about optimal management of ...

Kura Oncology and Kyowa Kirin announce FDA acceptance and Priority Review of New Drug Application for ziftomenib in adults with relapsed or refractory NPM1-mutant AML. News release. Kura Oncology.

– New Drug Application based on positive results from the Phase 2 KOMET-001 trial – – FDA assigns a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025 ...

The NPM1 mutation affects about 30% of all AML patients. In almost half of those patients, relapse or resistance to standard treatments occurs within a year of treatment.

Here we present the primary analysis for NPM1-m patients (pts) treated with ziftomenib 600 mg QD in the pivotal KOMET-001 study. Methods: KOMET-001 (NCT04067336) is a multicenter, open-label phase 1/2 ...

About NPM1 -Mutant AML . AML is the most common acute leukemia in adults and begins when the bone marrow makes abnormal myeloblasts (white blood cells), red blood cells or platelets.

The company noted that the NDA is based on results from the Phase 2 KOMET-001 registrational trial in R/R NPM1-mutant (NPM1-m) AML. The KOMET-001 trial achieved its primary endpoint of complete ...

Kura Oncology and Kyowa Kirin have shared details of the phase 2 win for their oral leukemia treatment ziftomenib as the FDA mulls whether to greenlight the selective menin inhibitor.

Adult patients with NPM1-m AML and select co-mutations and/or R/R disease have a poor prognosis, with median overall survival of only approximately 7.8 months in 2 nd line, 5.3 months in 3 rd line, ...